Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

695.33 -16.35 (-2.30%)
Official Closing Price Updated: 4:10 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Market Monitor News August 08 BMO - Tariffs, Tablets, and Turbulence: Wall Street Sways Under Trade War Fears and Pharma Fallout
Wall Street ended Thursday on a shaky note as disappointing drug trial results, new trade tariffs, and cautious corporate guidance weighed on sentiment. While Apple (AAPL | +3.2%) basked in the glow of... 
Via Chartmill
Topics World Trade
The Trade Desk, SoundHound AI, Eli Lilly, Block And CrowdStrike: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market saw a mixed performance today, with the Nasdaq gaining over 70 points, reflecting a 0.35% increase to 21,242.70 
Via Benzinga
Topics Artificial Intelligence
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound
Via Stocktwits
Eli Lilly Stock Sell-Off ‘Overdone’ As Weight-Loss Pill Remains ‘Commercially Viable’
Eli Lilly's late-stage data for weight-loss pill falls short of expectations. 
Via Talk Markets
Intel, Eli Lilly, Fortinet, Duolingo, Nebius: Stocks Making The Biggest Moves Today
Via Stocktwits
Eli Lilly’s Oral Obesity Drug Leads To Over 12% Weight Loss In Late-stage Study
Via Stocktwits
Eli Lilly Shares Tumble After Disappointing Weight-Loss Pill Data
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98... 
Via MarketMinute
Will Gilead's Beat-And-Raise Help It Leapfrog Its 50-Day Line Ceiling?
Gilead Sciences boosted its full-year outlook after beating expectations. Gilead stock is hitting a 50-day line ceiling. 
Via Investor's Business Daily
Why Eli Lilly (LLY) Shares Are Getting Obliterated Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss drug trial results disappointed investors, overshadowing an otherwise strong... 
Via StockStory
Stay informed with the top movers within the S&P500 index on Thursday.
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Eli Lilly (NYSE:LLY) Reports Bullish Q2 But Stock Drops 14.4%
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 37.6% year on year to $15.56 billion. The company’s full-year revenue... 
Via StockStory
Elanco (NYSE:ELAN) Delivers Impressive Q2, Stock Jumps 15.4%
Animal health company Elanco (NYSE:ELAN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.8% year on year to $1.24 billion. Guidance for next quarter’s revenue was... 
Via StockStory
Why Eli Lilly Stock Is Plunging Today
Lilly's late-stage results for its experimental oral obesity drug raised concerns. 
Via The Motley Fool
Eli Lilly Co. Q2 FY2025 Earnings Transcript
Eli Lilly delivered a strong Q2 2025 with 38% revenue growth and major clinical milestones, despite a selloff over obesity drug trial data. 
Via Benzinga
Why Are Eli Lilly’s Shares Crashing Today Despite Strong Earnings?
Eli Lilly's stock crashed over 14% despite strong Q2 earnings, as disappointing weight-loss pill trial results overshadowed 38% revenue growth and raised guidance. 
Via Talk Markets
Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: What's Moving Markets Thursday?
U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names. 
Via Benzinga
Topics Government World Trade
Upcoming Earnings Calls This Week: August 4th - August 10th, 2025
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial... 
Via MarketMinute
Topics Artificial Intelligence Economy
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
Exploring the top movers within the S&P500 index during today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Intel Stock Falls After Trump Says CEO 'Must Resign'
Intel stock fell after President Trump said CEO Lip-Bu Tan "must resign," saying he is "highly conflicted." 
Via Investor's Business Daily
Topics Government Law Enforcement
Thursday's session: gap up and gap down stock in the S&P500 index
Thursday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session. 
Via Chartmill
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates. 
Via Benzinga
Eli Lilly (LLY) Q2 Revenue Jumps 38%
Via The Motley Fool
Topics Intellectual Property
Lilly Shares Tumble As Weak Weight-Loss Pill Data Overshadows Strong Earnings
Eli Lilly shares plunged in premarket trading after disappointing results from its new weight-loss drug overshadowed strong second-quarter results and raised full-year guidance. 
Via Talk Markets
Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge.
An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise. 
Via Investor's Business Daily
Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk
Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 earnings beat and raised guidance. 
Via Benzinga
Topics Earnings
These S&P500 stocks are moving in today's pre-market session
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday? 
Via Chartmill
Eli Lilly & Co (NYSE:LLY) Reports Strong Q2 2025 Earnings Beat but Faces Pre-Market Decline Amid Market Skepticism
Eli Lilly (LLY) beat Q2 2025 earnings with strong Mounjaro & Zepbound demand, but shares fell 13% pre-market amid profit-taking and high expectations. Raised guidance signals confidence. 
Via Chartmill
Topics Earnings
Peloton Reportedly Laying Off 6% Of Its Staff In Another Round Of Job Cuts To Trim Expenses
According to a CNBC report, the company plans to reduce run-rate expenses by another $100 million in fiscal year 2026, on top of the $200 million it cut in fiscal 2025, half of which will come from... 
Via Stocktwits
Topics Workforce
Dow Futures Rise As Trump’s Reciprocal Tariff Deadline Kicks In: AAPL, NVDA, INTC, LLY, SRPT Among Stocks To Watch
Via Stocktwits
Topics Government Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.